No photo of Barbara Pro

View Scopus Profile

Barbara Pro

  • 8247 Citations
20002021
If you made any changes in Pure, your changes will be visible here soon.

Grants 2006 2021

Active

Prot #VS-0145-225: A Muti-Center, Phase 2, Open Label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Pro, B.

Parexel, Verastem, Inc.

8/6/18 → 8/6/21

Project: Research project

Prot #APL-B-021-13: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Pro, B.

Pharma Mar, S.A. Sociedad Unipersonal

2/28/17 → 2/28/20

Project: Research project

Prot #X16042: A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

Pro, B.

Millennium Pharmaceuticals, Inc

6/1/15 → 6/1/21

Project: Research project

Prot #RV-CL-PTCL-PI-003974: NU 14H04: Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL

Pro, B.

Celgene Corporation

5/14/15 → 5/14/21

Project: Research project

Prot #BO29337: A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison with BR Alone or GDC-0199 Plus Rituximab (R) in Patients with Relapsed and Refractory Follicular Non-H

Pro, B.

Covance Inc., Genentech, Inc.

4/10/15 → 4/30/20

Project: Research project

Prot #PCI-32765MCL2003: NU 14H06: A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Kaplan, J. B. & Pro, B.

Janssen Scientific Affairs, LLC

1/6/15 → 1/6/21

Project: Research project

Prot #C25003: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Pro, B.

ICON Clinical Research, LLC, Millennium Pharmaceuticals, Inc

10/2/13 → 10/31/20

Project: Research project

Finished

Prot #D4190C00023: A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Pro, B.

ICON Clinical Research, LLC, MedImmune, LLC

4/29/16 → 4/29/19

Project: Research project

Prot #NU 12H09: A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

Kaplan, J. B. & Pro, B.

Seattle Genetics, Inc.

2/26/13 → 2/26/19

Project: Research project

Prot #0761-010: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Kuzel, T. M. & Pro, B.

Kyowa Hakko Kirin Pharma, Inc.

2/12/13 → 2/12/19

Project: Research project

Prot# C25001: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Kuzel, T. M. & Pro, B.

ICON Clinical Research, LLC, Millennium Pharmaceuticals, Inc

6/15/12 → 6/15/18

Project: Research project

Prot# H3E-US-X065 / NU 05H8: Phase I/II Trial of Gemcitabine/Pemetrexed Combination in Patients with Advanced Cutaneous T-Cell Lymphoma

Guitart, J., Kuzel, T. M. & Pro, B.

Eli Lilly and Company

6/7/06 → 9/30/13

Project: Research project